Significant improvement in recurrence-free survival when capecitabine is integrated into docetaxel epirubicin plus cyclophosphamide adjuvant therapy for high-risk early breast cancer: interim analysis of the FinXX trial
- H Joensuu (Contributor)
- Kellokumpu-Lehtinen, P. (Contributor)
- R Huovinen (Contributor)
- Jukkola-Vuorinen, A. (Contributor)
- R Asola (Contributor)
- R Kokko (Contributor)
- J Ahlgren (Contributor)
- P Bono (Contributor)
- M Tanner (Contributor)
- M Lindman (Contributor)
Aktiviteetti: Konferenssiesitelmä